[1] |
FENG Xinying, WANG Bing, LIU Peifeng.
Innovations and challenges in intraperitoneal chemotherapy for peritoneal metastatic carcinoma
[J]. China Oncology, 2024, 34(9): 827-837.
|
[2] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
[3] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[4] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[5] |
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan.
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(7): 669-679.
|
[6] |
HUANG Sijie, KANG Xun, LI Wenbin.
Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
[J]. China Oncology, 2024, 34(7): 695-701.
|
[7] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[8] |
LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui.
Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy
[J]. China Oncology, 2024, 34(3): 278-285.
|
[9] |
FENG Huizhi, LIU Jingmei, BU Xiaoqian.
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
[J]. China Oncology, 2024, 34(11): 1028-1035.
|
[10] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
[11] |
CHU Yajuan, ZHANG Lei, LI Yunhai, LUO Weiming, ZHANG Jing, MO Xiaochen, MA Jinli.
Exploring the attenuating effect of amifostine on neoadjuvant radiotherapy with concurrent use of irinotecan for locally advanced rectal cancer: a retrospective cohort study of 154 cases
[J]. China Oncology, 2024, 34(10): 957-965.
|
[12] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Receptor discordance between primary breast cancer and liver metastases
[J]. China Oncology, 2023, 33(9): 834-843.
|
[13] |
WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong.
The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer
[J]. China Oncology, 2023, 33(9): 844-856.
|
[14] |
CHEN Jinjuan, WANG Xingran, LI Wenzhi, CHENG Yu, SUN Yihua, TAO Xiang, MA Fenghua, SUN Li, ZHAO Hongbo, LU Xin.
Conservative surgery in stage I placental site trophoblastic tumor: a report of 10 cases and literature review
[J]. China Oncology, 2023, 33(9): 857-865.
|
[15] |
SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo.
The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism
[J]. China Oncology, 2023, 33(8): 726-739.
|